ImmunityBio (IBRX) Capital Expenditures (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Capital Expenditures of $1.1 million for Q1 2026, up 32.83% quarter-over-quarter from $792000.0 in Q4 2025.
ImmunityBio (IBRX) Capital Expenditures (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Capital Expenditures for 13 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $2.4 million (up 1673.2% YoY), while the FY2025 annual figure was $1.4 million, up 22.29% from the prior year.
- Capital Expenditures rose to $1.1 million in Q1 2026 per IBRX's latest filing, from $792000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $43.4 million in Q2 2022 and bottomed at -$12.7 million in Q4 2023.
- Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 63919.12% — and 2025, when it slumped 191.98%.
- ImmunityBio's Capital Expenditures stood at $18.9 million in 2022, then tumbled by 166.91% to -$12.7 million in 2023, then jumped by 71.03% to -$3.7 million in 2024, then soared by 121.59% to $792000.0 in 2025, then jumped by 32.83% to $1.1 million in 2026.
- Business Quant data shows IBRX's Capital Expenditures at $1.1 million in Q1 2026, $792000.0 in Q4 2025, and -$1.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.52 Mn |
| Jun 30, 2026 | 3.52 Mn |
| Mar 31, 2026 | 1.05 Mn |
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 792,000.00 |
| Dec 31, 2025 | 792,000.00 |
| Sep 30, 2025 | -1.64 Mn |
| Sep 30, 2025 | -1.64 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | -12.67 Mn |
| Dec 31, 2023 | -12.67 Mn |